1 / 1

Reblozyl(Luspatercept)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Artesunate for Injection is a critical drug used in the treatment of severe malaria, a life-threatening condition caused by the Plasmodium falciparum parasite. This intravenous formulation of artesunate acts quickly to reduce the parasite load and improve the clinical condition of patients, particularly in hospitalized individuals. As malaria can rapidly lead to complications such as cerebral malaria and severe anemia, the prompt administration of Artesunate for Injection is crucial for patient survival. The treatment should be followed by an appropriate oral antimalarial regimen for complete therapy.

Given its importance in treating severe malaria, Artesunate for Injection is generally administered in hospital settings, where patient status can be closely monitored. The drug is recommended to be used in combination with additional therapy for malaria caused by Plasmodium vivax or Plasmodium ovale to prevent recurrence. Due to potential side effects such as hemolytic anemia, close monitoring during treatment is necessary to ensure patient safety and the effectiveness of the drug.

Generic name

Reblozyl(Luspatercept)

English name

Luspatercept

Alternative Names

Reblozyl

Drug prices

Indications

REBLOZYL is an erythroid maturation agent indicated for the treatment of:

Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions

Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular RBC transfusions

Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require

Therapeutic Target

not specified in the specification

Active Ingredients

Luspatercept-aamt

Dosage form

INJECTION

specifications

25 mg white to off-white lyophilized powder in a single-dose vial，75 mg white to off-white lyophilized powder in a single-dose vial

Description

REBLOZYL is a colorless to slightly yellow, clear to slightly opalescent solution after reconstitution. Each single-dose vial contains luspatercept-aamt, a recombinant fusion protein.

Dosage and Administration

Recommended Dosage:

Adults: 5 mg once daily orally, with or without food. Adjust based on clinical response and tolerability.

Renal Impairment (eGFR <30 mL/min): Reduce dose to 2.5 mg daily.

Hepatic Impairment (Child-Pugh B): Avoid use; insufficient data for Child-Pugh C.

Administration Instructions:

Swallow tablets whole; do not crush or split.

Missed Dose: Take as soon as remembered unless within 12 hours of next dose.

CATEGORY NAVIGATION